Pixantrone, a new anticancer drug with the same old cardiac problems? An in vitro study with differentiated and non-differentiated H9c2 cells

Open access


Pixantrone (PIX) is an anticancer drug approved for the treatment of multiple relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. It is an aza-anthracenedione synthesized to have the same anticancer activity as its predecessors, anthracyclines (e.g. doxorubicin) and anthracenediones (e.g. mitoxantrone), with lower cardiotoxicity. However, published data regarding its possible cardiotoxicity are scarce. Therefore, this work aimed to assess the potential cytotoxicity of PIX, at clinically relevant concentrations (0.1; 1; and 10 µM) in both non-differentiated and 7-day differentiated H9c2 cells. Cells were exposed to PIX for 48 h and cytotoxicity was evaluated through phase contrast microscopy, Hoescht staining and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) reduction and neutral red (NR) uptake assays. Cytotoxicity was observed in differentiated and non-differentiated H9c2 cells, with detached cells and round cells evidenced by phase contrast microscopy, mainly at the highest concentration tested (10 µM). In the Hoechst staining, PIX 10 µM showed a marked decrease in the number of cells when compared to control but with no signs of nuclear condensation. Furthermore, significant concentration-dependent mitochondrial dysfunction was observed through the MTT reduction assay. The NR assay showed similar results to those obtained in the MTT reduction assay in both differentiated and non-differentiated H9c2 cells. The differentiation state of the cells was not crucial to PIX effects, although PIX toxicity was slightly higher in differentiated H9c2 cells. To the best of our knowledge, this was the first in vitro study performed with PIX in H9c2 cells and it discloses worrying cytotoxicity at clinically relevant concentrations.

Beggiolin G, Crippa L, Menta E, Manzotti C, Cavalletti E, Pezzoni G, Torriani D, Randisi E, Cavagnoli R, Sala F, Giuliani FC, Spinelli S. (2001). Bbr 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity. Tumori 87: 407–416.

Borchmann P, Morschhauser F, Parry A, Schnell R, Harousseau JL, Gisselbrecht C, Rudolph C, Wilhelm M, Gunther H, Pfreundschuh DM, Camboni G, Engert A. (2003). Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin’s lymphomas. Haematologica 88: 888–894.

Capranico G, Tinelli S, Austin CA, Fisher ML, Zunino F. (1992). Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development. Biochim Biophys Acta 1132: 43–48.

Cavalletti E, Crippa L, Mainardi P, Oggioni N, Cavagnoli R, Bellini O, Sala F. (2007). Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone. Invest New Drugs 25: 187–195.

Conner CS. (1984). Mitoxantrone: a replacement for doxorubicin? Drug Intell Clin Pharm 18: 479–480.

Corbett TH, Griswold DP Jr., Roberts BJ, Schabel FM Jr. (1981). Absence of delayed lethality in mice treated with aclacinomycin A. Cancer Chemother Pharmacol 6: 161–168.

Costa VM, Carvalho F, Bastos ML, Carvalho RA, Carvalho M, Remião F. (2011). Contribution of catecholamine reactive intermediates and oxidative stress to the pathologic features of heart diseases. Curr Med Chem 18: 2272–2314.

Costa VM, Carvalho F, Duarte JA, Bastos ML, Remiao F. (2013). The heart as a target for xenobiotic toxicity: the cardiac susceptibility to oxidative stress. Chem Res Toxicol 26: 1285–1311.

Costa VM, Silva R, Tavares LC, Vitorino R, Amado F, Carvalho F, Bastos ML, Carvalho M, Carvalho RA, Remiao F. (2009). Adrenaline and reactive oxygen species elicit proteome and energetic metabolism modifications in freshly isolated rat cardiomyocytes. Toxicology 260: 84–96.

Dawson LK, Jodrell DI, Bowman A, Rye R, Byrne B, Bernareggi A, Camboni G, Smyth JF. (2000). A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly. Eur J Cancer 36: 2353–2359.

El-Helw LM, Hancock BW. (2007). Pixantrone: a novel aza-anthracenedione in the treatment of non-Hodgkin’s lymphomas. Expert Opin Investig Drugs 16: 1683–1691.

EMA. (2017). Pixuvri (pixantrone): EU summary of product characteristics. European Medicines Agency, London, UK.

Faivre S, Raymond E, Boige V, Gatineau M, Buthaut X, Rixe O, Bernareggi A, Camboni G, Armand JP. (2001). A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies. Clin Cancer Res 7: 43–50.

FDA. (2010). FDA ODAC Briefing Document: Pixuvri (pixantrone). In: U.S.D.o.H.a.H. Services (Ed), Maryland, USA.

Hasinoff BB, Wu X, Patel D, Kanagasabai R, Karmahapatra S, Yalowich JC. (2016). Mechanisms of action and reduced cardiotoxicity of pixantrone; a topoisomerase II targeting agent with cellular selectivity for the topoisom-erase II alpha isoform. J Pharmacol Exp Ther 356: 397–409.

Herman EH, Zhang J, Hasinoff BB, Clark JR Jr., Ferrans VJ. (1997). Comparison of the structural changes induced by doxorubicin and mitoxantrone in the heart, kidney and intestine and characterization of the Fe(III)-mitoxantrone complex. J Mol Cell Cardiol 29: 2415–2430.

Hescheler J, Meyer R, Plant S, Krautwurst D, Rosenthal W, Schultz G. (1991). Morphological, biochemical, and electrophysiological characterization of a clonal cell (H9c2) line from rat heart. Circ Res 69: 1476–1486.

Hrynchak I, Sousa E, Pinto M, Costa VM. (2017). The importance of drug metabolites synthesis: the case-study of cardiotoxic anticancer drugs. Drug Metab Rev 49: 158–196.

Kimes BW, Brandt BL. (1976). Properties of a clonal muscle cell line from rat heart. Exp Cell Res 98: 367–381.

Kluza J, Marchetti P, Gallego MA, Lancel S, Fournier C, Loyens A, Beauvillain JC, Bailly C. (2004). Mitochondrial proliferation during apoptosis induced by anticancer agents: effects of doxorubicin and mitoxantrone on cancer and cardiac cells. Oncogene 23: 7018–7030.

Krapcho AP, Petry ME, Getahun Z, Landi JJJr, Stallman J, Polsenberg JF, Gallagher CE, Maresch MJ, Hacker MP, Giuliani FC, Beggiolin G, Pezzoni G, Menta E, Manzotti C, Oliva A, Spinelli S, Tognella S. (1994). 6,9-Bis[(aminoalkyl) amino]benzo[g]isoquinoline-5,10-diones. A novel class of chromophore-modified antitumor anthracene-9,10-diones: synthesis and antitumor evaluations. J Med Chem 37: 828–837.

Lopes MA, Meisel A, Dirnagl U, Carvalho FD, Bastos ML. (2008). Doxorubicin induces biphasic neurotoxicity to rat cortical neurons. Neurotoxicology 29: 286–293.

Malisza KL, Hasinoff BB. (1995). Production of hydroxyl radical by iron(III)-anthraquinone complexes through self-reduction and through reductive activation by the xanthine oxidase/hypoxanthine system. Arch Biochem Biophys 321: 51–60.

Menard C, Pupier S, Mornet D, Kitzmann M, Nargeot J, Lory P. (1999). Modulation of L-type calcium channel expression during retinoic acid-induced differentiation of H9c2 cardiac cells. J Biol Chem 274: 29063–29070.

Péan E, Flores B, Hudson I, Sjöberg J, Dunder K, Salmonson T, Gisselbrecht C, Laane E, Pignatti F. (2013). The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-hodgkin’s b-cell lymphomas: Summary of the scientific assessment of the committee for medicinal products for human use. Oncologist 18: 625–633.

Pettengell R, Coiffier B, Narayanan G, de Mendoza FH, Digumarti R, Gomez H, Zinzani PL, Schiller G, Rizzieri D, Boland G, Cernohous P, Wang L, Kuepfer C, Gorbatchevsky I, Singer JW. (2012). Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. Lancet Oncol 13: 696–706.

Reis-Mendes A, Gomes AS, Carvalho RA, Carvalho F, Remiao F, Pinto M, Bastos ML, Sousa E, Costa VM. (2017). Naphthoquinoxaline metabolite of mitoxantrone is less cardiotoxic than the parent compound and it can be a more cardiosafe drug in anticancer therapy. Arch Toxicol 91: 1871–1890.

Reis-Mendes AF, Sousa E, de Lourdes Bastos M, Costa VM. (2015). The role of the metabolism of anticancer drugs in their induced-cardiotoxicity. Curr Drug Metab 17: 75–90.

Repetto G, del Peso A, Zurita JL. (2008). Neutral red uptake assay for the estimation of cell viability/cytotoxicity. Nat Protoc 3: 1125–1131.

Rossato LG, Costa VM, Dallegrave E, Arbo M, Silva R, Ferreira R, Amado F, Dinis-Oliveira RJ, Duarte JA, de Lourdes Bastos M, Palmeira C, Remiao F. (2014). Mitochondrial cumulative damage induced by mitoxantrone: late onset cardiac energetic impairment. Cardiovasc Toxicol 14: 30–40.

Rossato LG, Costa VM, Vilas-Boas V, de Lourdes Bastos M, Rolo A, Palmeira C, Remiao F. (2013). Therapeutic concentrations of mitoxantrone elicit energetic imbalance in H9c2 cells as an earlier event. Cardiovasc Toxicol 13: 413–425.

Ruiz M, Courilleau D, Jullian JC, Fortin D, Ventura-Clapier R, Blondeau JP, Garnier A. (2012). A cardiac-specific robotized cellular assay identified families of human ligands as inducers of PGC-1alpha expression and mitochondrial biogenesis. PLoS One 7: e46753.

Salvatorelli E, Menna P, Paz OG, Chello M, Covino E, Singer JW, Minotti G. (2013). The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients. J Pharmacol Exp Ther 344: 467–478.

Sardão VA, Oliveira PJ, Holy J, Oliveira CR, Wallace KB. (2009). Doxorubicin-induced mitochondrial dysfunction is secondary to nuclear p53 activation in H9c2 cardiomyoblasts. Cancer Chemother Pharmacol 64: 811–827.

Soares AS, Costa VM, Diniz C, Fresco P. (2013). Potentiation of cytotoxicity of paclitaxel in combination with Cl-IB-MECA in human C32 metastatic melanoma cells: A new possible therapeutic strategy for melanoma. Biomed Pharmacother 67: 777–789.

Stuart-Harris RC, Bozek T, Pavlidis NA, Smith IE. (1984). Mitoxantrone: an active new agent in the treatment of advanced breast cancer. Cancer Che-mother Pharmacol 12: 1–4.

Volpetti S, Zaja F, Fanin R. (2014). Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas. Onco Targets Ther 7: 865–872.

Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, Yeh ET. (2012). Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 18: 1639–1642.

Zhang YY, Meng C, Zhang XM, Yuan CH, Wen MD, Chen Z, Dong DC, Gao YH, Liu C, Zhang Z. (2015). Ophiopogonin D attenuates doxorubicin-induced autophagic cell death by relieving mitochondrial damage in vitro and in vivo. J Pharmacol Exp Ther 352: 166–174.

Zordoky BN, El-Kadi AO. (2007). H9c2 cell line is a valuable in vitro model to study the drug metabolizing enzymes in the heart. J Pharmacol Toxicol Methods 56: 317–322.

Interdisciplinary Toxicology

The Journal of Institute of Experimental Pharmacology of Slovak Academy of Sciences

Journal Information

CiteScore 2017: 2.36

SCImago Journal Rank (SJR) 2017: 0.580
Source Normalized Impact per Paper (SNIP) 2017: 1.134


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 243 243 37
PDF Downloads 213 213 24